We extend our sincere appreciation for the support of our corporate sponsors. Their generosity provides vital funding needed to fulfill our mission to make a lasting and positive difference in the lives of people who have kidney disease.
THANK YOU TO OUR CORPORATE PARTNERS
Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA), provides dialysis treatment and services to more than 190,000 people with kidney disease at more than 2,400 facilities nationwide. Fresenius Kidney Care supports people by helping to address both the physical and emotional aspects of kidney disease through personalized care, education and lifestyle support services so they can lead meaningful and fulfilling lives.
U.S. Renal Care serves more than 23,000 patients in 300 dialysis facilities in 31 states and the Territory of Guam with a unique business model, developing and operating dialysis centers in joint venture partnerships with leading local nephrologists.
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.
Akebia Therapeutics is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
At Vifor Pharma, we are dedicated to finding the right treatment solutions for patients. Over several decades, we have proven our ability to identify and serve therapeutic areas with significant unmet medical need, successfully building on our expertise and track record to create new markets.
We have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease. This is supported by our founding heritage and expertise in iron deficiency therapy, helping to support a broad range of patients in need.
OneLegacy saves and heals lives through organ, eye and tissue donation, comforts the families we serve, and inspires our communities to Donate Life. OneLegacy envisions a day when we fulfill the needs of donor families and all who require organ, cornea or tissue transplants for their health and well-being. We commit ourselves to continuously improve the quality of our practices, performance, and service to our communities.
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.
We are developing an innovative and proprietary method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care across numerous therapeutic areas.
With Facilitated Allo-HSCT Therapy, we aim to remove solid organ transplantation recipients’ need for chronic immunosuppression and treat patients who suffer from severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders.